Clinical Trial Update: Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/Phase 2 trial evaluated whether pomegranate extract could affect cardiovascular risk markers in overweight healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overweight

Drugs mentioned

• Pomegranate Extract

Snippet

Sponsor: National Research Council, Spain | Conditions: Overweight | Phase 1, Phase 2 | Status: COMPLETED